{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:56Z","timestamp":1790912516716,"version":"4.1.0"},"reference-count":117,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: The varicella\u2013zoster virus (VZV) is a human herpesvirus that primarily causes varicella (chickenpox) as an initial infection, characterized by distinctive skin lesions. It can later reactivate, leading to herpes zoster (shingles). Once reactivated, VZV infection may result in serious complications, the most common being postherpetic neuralgia. Fortunately, vaccination can prevent this condition. Objectives: In this study, we provide a comprehensive analysis of zoster vaccines, including clinical trials, safety profiles, and reimbursement guidelines across various countries. Results: Our findings confirm the vaccine\u2019s effectiveness and safety across diverse populations, aligning with previous clinical trials and real-world data, and summarize global vaccination guidelines.<\/jats:p>","DOI":"10.3390\/vaccines13050477","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:00:39Z","timestamp":1745917239000},"page":"477","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Herpes Zoster Vaccination: Insights into Efficacy, Safety, and Guidelines"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2635-0856","authenticated-orcid":false,"given":"Micha\u0142","family":"Oleszko","sequence":"first","affiliation":[{"name":"College of Medical Sciences, University of Rzesz\u00f3w, 35-315 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9935-472X","authenticated-orcid":false,"given":"Pawe\u0142","family":"Zapolnik","sequence":"additional","affiliation":[{"name":"College of Medical Sciences, University of Rzesz\u00f3w, 35-315 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-7967","authenticated-orcid":false,"given":"Hanna","family":"Czajka","sequence":"additional","affiliation":[{"name":"College of Medical Sciences, University of Rzesz\u00f3w, 35-315 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tung, Y.C., Tu, H.P., Wu, M.K., Kuo, K.L., Su, Y.F., Lu, Y.Y., Lin, C.L., and Wu, C.H. (2020). Higher risk of herpes zoster in stroke patients. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228409"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40121-022-00717-6","article-title":"Hospitalization Burden Related to Herpes Zoster Infection in Spain (2016\u20132019)","volume":"12","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.vaccine.2019.11.054","article-title":"The burden of herpes zoster disease in Norway","volume":"38","author":"Mirinaviciute","year":"2020","journal-title":"Vaccine"},{"key":"ref_5","unstructured":"(2025, March 03). Ministerio de Sanidad, Herpes Zoster: Recomendaciones Vacunacion, Available online: https:\/\/www.sanidad.gob.es\/en\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/programasDeVacunacion\/docs\/HerpesZoster_RecomendacionesVacunacion.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.coi.2019.02.005","article-title":"Understanding the immunology of the Zostavax shingles vaccine","volume":"59","author":"Sullivan","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.cell.2017.04.026","article-title":"Metabolic Phenotypes Of Response to Vaccination in Humans","volume":"169","author":"Li","year":"2017","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1016\/j.vaccine.2017.11.013","article-title":"Herpes zoster vaccine live: A 10 year review of post-marketing safety experience","volume":"35","author":"Willis","year":"2017","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50\u201359 Years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.jvacx.2019.100007","article-title":"Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England","volume":"1","author":"Bollaerts","year":"2019","journal-title":"Vaccine X"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: Current status and future prospects","volume":"51","author":"Oxman","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","unstructured":"European Medicines Agency (2025, March 03). Zostavax (Shingles [Herpes Zoster]) Vaccine [live]): Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zostavax-epar-product-information_en.pdf."},{"key":"ref_15","unstructured":"(2025, March 03). Shingrix Product Monograph. Available online: https:\/\/ca.gsk.com\/media\/6259\/shingrix-pm-en.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1016\/j.vaccine.2018.05.078","article-title":"Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection","volume":"36","author":"Alexander","year":"2018","journal-title":"Vaccine"},{"key":"ref_17","first-page":"134","article-title":"Zaka\u017cenia wirusem p\u00f3\u0142pa\u015bca\u2014epidemiologia, diagnostyka i profilaktyka w \u015bwietle rosn\u0105cego problemu klinicznego","volume":"3","author":"Giannopoulos","year":"2023","journal-title":"Hematol.-Eduk."},{"key":"ref_18","unstructured":"(2025, March 03). Shingrix Package Insert. Available online: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Shingrix\/pdf\/SHINGRIX.PDF."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.vaccine.2019.11.058","article-title":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","volume":"38","author":"Co","year":"2020","journal-title":"Vaccine"},{"key":"ref_21","unstructured":"(2025, March 03). Clinical Considerations for Shingrix Use in Immunocompromised Adults Aged \u226519 Years|Shingles (Herpes Zoster)|CDC, Available online: https:\/\/www.cdc.gov\/shingles\/hcp\/vaccine-considerations\/immunocompromised-adults.html."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","article-title":"Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial","volume":"169","author":"Marchant","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"0075_5167","DOI":"10.4049\/jimmunol.212.supp.0075.5167","article-title":"Trained Immunity Generated by The Recombinant Zoster Vaccine (RZV)","volume":"212","author":"Johnson","year":"2024","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40257-019-00483-1","article-title":"Herpes Zoster Presentation, Management, and Prevention: A Modern Case-Based Review","volume":"21","author":"Rosamilia","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged \u226519 Years: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_28","unstructured":"CDC and Ncird (2025, March 03). Advisory Committee on Immunization Practices (ACIP) General Best Guidance for Immunization, Available online: www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/downloads\/general-recs.pdf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.vaccine.2024.02.035","article-title":"Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview","volume":"42","author":"Ali","year":"2024","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1038\/s41591-024-03201-5","article-title":"The recombinant shingles vaccine is associated with lower risk of dementia","volume":"30","author":"Taquet","year":"2024","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Eyting, M., Xie, M., Michalik, F., He\u00df, S., Chung, S., and Geldsetzer, P. (2025). A natural experiment on the effect of herpes zoster vaccination on dementia. Nature, 1\u20139.","DOI":"10.1038\/s41586-025-08800-x"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"126673","DOI":"10.1016\/j.vaccine.2024.126673","article-title":"Recombinant zoster vaccine and the risk of dementia","volume":"46","author":"Tang","year":"2025","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2263979","DOI":"10.1080\/21645515.2023.2263979","article-title":"Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence","volume":"19","author":"Parikh","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1016\/j.vaccine.2024.03.066","article-title":"Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia","volume":"42","author":"Muttucumaru","year":"2024","journal-title":"Vaccine"},{"key":"ref_35","unstructured":"USFD (2025, March 03). SHINGRIX, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/shingrix."},{"key":"ref_36","unstructured":"GSK (2025, March 03). Announces First Approval of Shingrix in Canada|GSK. Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-announces-first-approval-of-shingrix-in-canada\/."},{"key":"ref_37","unstructured":"GSK (2025, March 03). Shingrix Approved in Europe and Japan for the Prevention of Shingles in Adults Aged 50 and over. Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/shingrix-approved-in-europe-and-japan-for-the-prevention-of-shingles-in-adults-aged-50-and-over."},{"key":"ref_38","unstructured":"Therapeutic Goods Administration (2025, March 03). SHINGRIX (GlaxoSmithKline Australia Pty Ltd), Available online: https:\/\/www.tga.gov.au\/resources\/prescription-medicines-registrations\/shingrix-glaxosmithkline-australia-pty-ltd."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sei, J.J., Cox, K.S., Dubey, S.A., Antonello, J.M., Krah, D.L., Casimiro, D.R., and Vora, K.A. (2015). Effector and Central Memory Poly-Functional CD4+ and CD8+ T Cells are Boosted upon ZOSTAVAX\u00ae Vaccination. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00553"},{"key":"ref_42","unstructured":"GlaxoSmithKline Biologicals (2025, March 03). Shingrix (Zoster Vaccine Recombinant, Adjuvanted) Suspension for Intramuscular Injection-Highlights of Prescribing Information, Available online: https:\/\/www.fda.gov\/media\/108597\/download."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3949\/ccjm.91a.24019","article-title":"Preventing herpes zoster in immunocompromised patients: Current concepts","volume":"91","author":"Calabrese","year":"2024","journal-title":"Clevel. Clin. J. Med."},{"key":"ref_44","unstructured":"European Medicines Agency (2025, March 03). Shingrix EPAR-Product Information. Available online: https:\/\/www.ema.europa.eu\/documents\/product-information\/shingrix-epar-product-information_en.pdf."},{"key":"ref_45","unstructured":"(2025, March 03). Proven Shingrix Protection. Available online: https:\/\/shingrixhcp.com\/efficacy-safety\/efficacy-data\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2351584","DOI":"10.1080\/21645515.2024.2351584","article-title":"Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults \u226550 years: A randomized, placebo-controlled trial","volume":"20","author":"Proano","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/infdis\/jiv164","article-title":"Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus","volume":"212","author":"Laing","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"ofaa172","DOI":"10.1093\/ofid\/ofaa172","article-title":"Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients with Solid or Hematologic Cancer","volume":"7","author":"Boeckh","year":"2020","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_49","unstructured":"(2021). In brief: Shingrix for immunocompromised adults. Med. Lett. Drugs Ther., 63, 129."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40264-021-01076-w","article-title":"Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials","volume":"44","author":"Bastidas","year":"2021","journal-title":"Drug Saf."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/cid\/ciab121","article-title":"Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study","volume":"73","author":"Sun","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100397","DOI":"10.1016\/j.jvacx.2023.100397","article-title":"Efficacy and safety of the recombinant zoster vaccine: A systematic review and meta-analysis","volume":"15","author":"Zeevaert","year":"2023","journal-title":"Vaccine X"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.vaccine.2019.04.014","article-title":"The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis","volume":"37","author":"McGirr","year":"2019","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"k4029","DOI":"10.1136\/bmj.k4029","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: Systematic review and network meta-analysis","volume":"363","author":"Tricco","year":"2018","journal-title":"BMJ"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2167907","DOI":"10.1080\/21645515.2023.2167907","article-title":"Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer","volume":"19","author":"Curran","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbmt.2016.12.620","article-title":"Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies","volume":"23","author":"Sahoo","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00592-023-02127-7","article-title":"Efficacy and effectiveness of Herpes zoster vaccination in adults with diabetes mellitus: A systematic review and meta-analysis of clinical trials and observational studies","volume":"60","author":"Silverii","year":"2023","journal-title":"Acta Diabetol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Xia, Y., Zhang, X., Zhang, L., and Fu, C. (2022). Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.978203"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2666-7568(22)00039-3","article-title":"Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: A systematic review and meta-analysis","volume":"3","author":"Mbinta","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e70285","DOI":"10.1002\/jmv.70285","article-title":"Recombinant Zoster Vaccine Reduces All-Cause Mortality, But Not Major Adverse Cardiovascular Events, in Patients with Immune-Mediated Inflammatory Diseases Receiving Janus Kinase Inhibitors: A Large-Scale Real-World Retrospective Cohort Study","volume":"97","author":"Shih","year":"2025","journal-title":"J. Med. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7326\/M23-2023","article-title":"Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting","volume":"177","author":"Zerbo","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1016\/j.vaccine.2019.09.028","article-title":"Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry\/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials","volume":"37","author":"Willer","year":"2019","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Losa, L., Antonazzo, I.C., Di Martino, G., Mazzaglia, G., Tafuri, S., Mantovani, L.G., and Ferrara, P. (2024). Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression. Vaccines, 12.","DOI":"10.3390\/vaccines12050527"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/infdis\/jiad132","article-title":"Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines","volume":"228","author":"Weinberg","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00240-21","DOI":"10.1128\/JVI.00240-21","article-title":"Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines","volume":"95","author":"Schmid","year":"2021","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Lindemann, M., Baumann, C., Wilde, B., G\u00e4ckler, A., Meller, L., Horn, P.A., Krawczyk, A., and Witzke, O. (2022). Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients. Vaccines, 10.","DOI":"10.3390\/vaccines10060844"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Koldehoff, M., Horn, P.A., and Lindemann, M. (2022). Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Vaccines, 10.","DOI":"10.3390\/vaccines10050809"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix)\u2014United States, October 2017\u2013June 2018","volume":"68","author":"Hesse","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/aje\/kwac170","article-title":"Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data","volume":"192","author":"Nelson","year":"2023","journal-title":"Am. J. Epidemiol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Venerito, V., Stefanizzi, P., Cantarini, L., Lavista, M., Galeone, M.G., Di Lorenzo, A., Iannone, F., Tafuri, S., and Lopalco, G. (2023). Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24086967"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1016\/j.vaccine.2024.03.024","article-title":"Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021\u20132023","volume":"42","author":"Stefanizzi","year":"2024","journal-title":"Vaccine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"E528","DOI":"10.1097\/RHU.0000000000001790","article-title":"A Medical Records Review Study Assessing Safety of Zoster Vaccine Recombinant, Adjuvanted in Patients with Rheumatic Disease","volume":"28","author":"Gupta","year":"2022","journal-title":"J. Clin. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/art.42261","article-title":"Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults with Immune-Mediated Inflammatory Diseases in the US","volume":"74","author":"Leung","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"125","DOI":"10.14423\/SMJ.0000000000001354","article-title":"Safety of Recombinant Zoster Vaccine in Rheumatology Patients","volume":"115","author":"Raza","year":"2022","journal-title":"South. Med. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s10620-019-06016-4","article-title":"Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease","volume":"65","author":"Satyam","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center\u2019s Experience With 400 Patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/ecco-jcc\/jjac040","article-title":"Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease","volume":"16","author":"Khan","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jsps.2022.10.001","article-title":"Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics\u2019 impact","volume":"30","author":"Almadani","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s40264-021-01118-3","article-title":"An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine","volume":"44","author":"Pirrotta","year":"2021","journal-title":"Drug Saf."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/aje\/kwac030","article-title":"A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine","volume":"191","author":"Yih","year":"2022","journal-title":"Am. J. Epidemiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/bloodadvances.2020003749","article-title":"Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation","volume":"5","author":"Baumrin","year":"2021","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/infdis\/jiab633","article-title":"Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults","volume":"225","author":"Bruxvoort","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Costantino, M., Giudice, V., Moccia, G., Longanella, W., Caruccio, S., Tremiterra, G., Sinopoli, P., Benvenuto, D., Serio, B., and Malatesta, F. (2024). Safety of Adjuvanted Recombinant Herpes Zoster Virus Vaccination in Fragile Populations: An Observational Real-Life Study. Vaccines, 12.","DOI":"10.3390\/vaccines12090990"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"102981","DOI":"10.1016\/j.pmedr.2025.102981","article-title":"Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017\u2013April 2024","volume":"50","author":"Shu","year":"2025","journal-title":"Prev. Med. Rep."},{"key":"ref_88","unstructured":"(2025, March 03). FDA Requires a Warning about Guillain-Barr\u00e9 Syndrome (GBS) be Included in the Prescribing Information for Shingrix, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-warning-about-guillain-barre-syndrome-gbs-be-included-prescribing-information-shingrix."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2060668","DOI":"10.1080\/21645515.2022.2060668","article-title":"Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults","volume":"18","author":"Janusz","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_90","unstructured":"Australian Government DoHaAC (2025, March 03). National Immunisation Program\u2013Changes to Shingles Vaccination from 1 November 2023, Available online: https:\/\/www.health.gov.au\/news\/national-immunisation-program-changes-to-shingles-vaccination-from-1-november-2023."},{"key":"ref_91","unstructured":"Centers for Disease Control and Prevention (2025, March 03). Shingles Vaccination, Available online: https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/public\/shingrix\/index.html."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of Adults With Cancer: ASCO Guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_93","unstructured":"(2025, March 03). Shingles Immunisation Programme: Information for Healthcare Practitioners-GOV.UK, Available online: https:\/\/www.gov.uk\/government\/publications\/shingles-vaccination-guidance-for-healthcare-professionals\/shingles-immunisation-programme-information-for-healthcare-practitioners."},{"key":"ref_94","unstructured":"(2025, March 03). Shingrix-Immunisation Advisory Centre. Available online: https:\/\/www.immune.org.nz\/vaccine\/shingrix."},{"key":"ref_95","unstructured":"(2025, March 03). Joint Committee on Vaccination and Immunisation Minute of the Meeting Held on 06 February 2019. Available online: https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/file\/424913874479."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"De Caro, F., Malatesta, F., Pecoraro, N., Capunzo, M., Carpinelli, L., Caruccio, S., Cersosimo, G., Costantino, M., Giordano, C., and Longanella, W. (2024). Anti-Herpes Zoster Vaccination of Fragile Patients in Hospital Setting: A Nudge Intervention in Italy. Vaccines, 12.","DOI":"10.3390\/vaccines12040442"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5604\/01.3001.0053.7732","article-title":"Herpes zoster vaccination recommendations of the group of experts of the Polish Society of Vaccinology, the Polish Society of Family Medicine, the Polish Society of Dermatology, the Polish Association for the Study of Pain and the Polish Neurological Society","volume":"24","author":"Kuchar","year":"2023","journal-title":"B\u00d3L"},{"key":"ref_98","first-page":"321","article-title":"Zapobieganie zaka\u017ceniom wirusem herpes zoster u chorych na nowotwory lite\u2014stanowisko ekspert\u00f3w","volume":"9","author":"Kucharz","year":"2023","journal-title":"Onkol. w Prakt. Klin.-Edukacja"},{"key":"ref_99","unstructured":"(2025, March 03). Introduction of Shingrix\u00ae Vaccine for the Whole Programme and Expansion of Eligible Cohorts Letter-GOV.UK, Available online: https:\/\/www.gov.uk\/government\/publications\/shingles-vaccination-programme-changes-from-september-2023-letter\/introduction-of-shingrix-vaccine-for-the-whole-programme-and-expansion-of-eligible-cohorts-letter."},{"key":"ref_100","unstructured":"(2025, March 03). The Immunisation Schedule, Available online: https:\/\/www.salute.gov.it\/portale\/vaccinazioni\/dettaglioContenutiVaccinazioni.jsp?id=5501&area=vaccinazioni&menu=vuoto."},{"key":"ref_101","unstructured":"(2024, October 04). Kostenlose Impfung Gegen G\u00fcrtelrose f\u00fcr Personen ab 65 Jahren und Personen mit Immunschw\u00e4che-Die Luxemburger Regierung. Available online: https:\/\/gouvernement.lu\/de\/actualites\/toutes_actualites\/communiques\/2023\/04-avril\/12-vaccin-gratuit-zona.html."},{"key":"ref_102","unstructured":"(2025, March 03). Estos son los Grupos de Vacunaci\u00f3n Frente a Herpes Z\u00f3ster. Available online: https:\/\/www.consalud.es\/pacientes\/infecciosas\/grupos-vacunacion-contra-herpes-zoster_135998_102.html."},{"key":"ref_103","unstructured":"(2025, March 03). Vaccine Scheduler|ECDC. Available online: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=51&SelectedCountryIdByDisease=-1."},{"key":"ref_104","unstructured":"Limia, A. (2025, March 03). Recomendaciones de vacunacio n frente a herpes zo ster Ponencia de Programa. Available online: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/programasDeVacunacion\/docs\/HerpesZoster_RecomendacionesVacunacion.pdf."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.jval.2022.09.452","article-title":"EE202 Estimating the Public Health Benefits of Preventing Herpes Zoster and Postherpetic Neuralgia in Greece by Zoster Vaccines: A Modelling Study","volume":"25","author":"Kotsopoulos","year":"2022","journal-title":"Value Health"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3934\/publichealth.2023061","article-title":"Vaccination coverage of primary care providers against seasonal influenza, tetanus, pneumococcal pneumonia and herpes zoster: A cross-sectional study in Greece","volume":"10","author":"Kalatzi","year":"2023","journal-title":"AIMS Public Health"},{"key":"ref_107","unstructured":"(2025, March 03). National Immunization Program of Greece 2024, Available online: https:\/\/www.moh.gov.gr\/articles\/health\/dieythynsh-dhmosias-ygieinhs\/emboliasmoi\/ethniko-programma-emboliasmwn-epe-enhlikwn\/12253-ethniko-programma-emboliasmwn-enhlikwn-2024?dl=1."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"126354","DOI":"10.1016\/j.vaccine.2024.126354","article-title":"Analysis of health claims data on vaccination coverage in older adults in Bavaria, Germany: Influenza, pneumococcus and herpes zoster","volume":"42","author":"Awuah","year":"2024","journal-title":"Vaccine"},{"key":"ref_109","unstructured":"(2025, March 03). RKI-Varizellen-G\u00fcrtelrose (Herpes Zoster): Antworten auf H\u00e4ufig Gestellte Fragen zu Erkrankung und Impfung. Available online: https:\/\/www.rki.de\/SharedDocs\/FAQ\/Herpes_zoster\/FAQ-Liste.html."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/17843286.2024.2350258","article-title":"Acta Clinica Belgica International Journal of Clinical and Laboratory Medicine Herpes zoster in Belgium: A new solution to an old problem","volume":"79","author":"Nikkels","year":"2024","journal-title":"Acta Clin. Belg."},{"key":"ref_111","unstructured":"(2025, March 03). Le Calendrier des Vaccinations-Minist\u00e8re de la Sant\u00e9 et de L\u2019acc\u00e8s aux Soins. Available online: https:\/\/sante.gouv.fr\/prevention-en-sante\/preserver-sa-sante\/vaccination\/calendrier-vaccinal."},{"key":"ref_112","unstructured":"(2025, March 03). Les Vaccins Devenus Obligatoires Sont-Ils Int\u00e9gralement Rembours\u00e9s ?-Minist\u00e8re de la Sant\u00e9 et de L\u2019acc\u00e8s aux Soins. Available online: https:\/\/sante.gouv.fr\/prevention-en-sante\/preserver-sa-sante\/vaccination\/vaccins-obligatoires\/questions-reponses\/article\/les-vaccins-devenus-obligatoires-sont-ils-integralement-rembourses."},{"key":"ref_113","unstructured":"Descriptif de la Publication Titre Recommandations Vaccinales Contre le Zona (2025, March 03). Place du Vaccin Shingrix. Available online: https:\/\/www.has-sante.fr\/jcms\/p_3498915\/fr\/recommandations-vaccinales-contre-le-zona-place-du-vaccin-shingrix."},{"key":"ref_114","unstructured":"(2025, March 03). Wniosek o Obj\u0119cie Refundacj\u0105 Szczepionki Shingrix we Wskazaniu: Profilaktyka P\u00f3\u0142pa\u015bca Oraz Neuralgii P\u00f3\u0142pa\u015bcowej w Grupie Os\u00f3b w Wieku 65 lat i Starszych Analiza Weryfikacyjna, Available online: https:\/\/bip.aotm.gov.pl\/assets\/files\/zlecenia_mz\/2024\/158\/AWA\/158_AWA_OT.423.0.7.2024_Shingrix_BIP_REOPTR.pdf."},{"key":"ref_115","unstructured":"(2025, April 02). Obwieszczenie Ministra Zdrowia z dnia 19 Marca 2025, r. w Sprawie Wykazu Refundowanych Lek\u00f3w, \u015arodk\u00f3w Spo\u017cywczych Specjalnego Przeznaczenia \u017bywieniowego Oraz Wyrob\u00f3w Medycznych na 1 Kwietnia 2025 r, Available online: https:\/\/www.gov.pl\/web\/zdrowie\/obwieszczenie-ministra-zdrowia-z-dnia-19-marca-2025-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-kwietnia-2025-r."},{"key":"ref_116","unstructured":"(2025, March 03). Cost & Coverage|SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted). Available online: https:\/\/www.shingrix.com\/get-shingrix\/shingles-vaccine-cost-coverage\/."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e43893","DOI":"10.2196\/43893","article-title":"Willingness to Vaccinate Against Herpes Zoster and Its Associated Factors Across WHO Regions: Global Systematic Review and Meta-Analysis","volume":"9","author":"Wang","year":"2023","journal-title":"JMIR Public Health Surveill."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/477\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:23:40Z","timestamp":1760030620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":117,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["vaccines13050477"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13050477","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}